推荐产品
化驗
99%
形狀
foil
製造商／商標名
Goodfellow 457-233-26
電阻係數
54 μΩ-cm
尺寸 × 厚度
50 x 50 mm × 0.1 mm
bp
3464 °C (lit.)
mp
920 °C (lit.)
密度
6.19 g/mL at 25 °C (lit.)
SMILES 字串
[La]
InChI
1S/La
InChI 密鑰
FZLIPJUXYLNCLC-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
For updated SDS information please visit www.goodfellow.com.
法律資訊
Product of Goodfellow
儲存類別代碼
4.3 - Hazardous materials which set free flammable gases upon contact with water
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Stuart M Sprague
Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
Amy Barton Pai et al.
Expert opinion on drug metabolism & toxicology, 5(1), 71-81 (2009-02-25)
Hyperphosphatemia is recognized as a principal mineral disorder in chronic kidney disease (CKD) that leads to the development of secondary hyperparathyroidism. Recent data indicate that hyperphosphatemia is associated with accelerated cardiac calcification and increased mortality in patients with CKD. Control
Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that
Mario Cozzolino et al.
Expert opinion on pharmacotherapy, 13(16), 2337-2353 (2012-10-05)
High phosphate levels are associated with unfavorable outcomes in ESRD. Recent data suggested that phosphate levels within the normal range are equally associated with poor outcomes in the community and CKD stage 3 - 4. Several concept papers support the
Declan de Freitas et al.
Seminars in dialysis, 20(4), 325-328 (2007-07-20)
Hyperphosphatemia is associated with increased morbidity and mortality in dialysis patients. Oral phosphate binders are necessary to control serum phosphate in patients eating a normal diet and undergoing peritoneal dialysis or thrice weekly hemodialysis. Until recently, none of the available
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门